NCT00076037View on ClinicalTrials.gov

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

June 30, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV CTL MEP administered with RC529-SE adjuvant

DRUG

GM-CSF

Trial Locations (7)

14642

Univ. of Rochester HVTN CRS, Rochester

37232

Vanderbilt Vaccine CRS, Nashville

98104

FHCRC/UW Vaccine CRS, Seattle

35294-2041

Alabama Vaccine CRS, Birmingham

Unknown

San Francisco Vaccine and Prevention CRS, San Francisco

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore, Baltimore

63110-2500

Saint Louis Univ. School of Medicine, HVTU, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00076037 - Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP | Biotech Hunter | Biotech Hunter